Guidelines and HEDIS® Measures for COPD: Strategies to Optimize Clinical and Economic Outcomes

Jointly sponsored by NCQA and Princeton CME

Target Audience

This activity is designed for medical directors, pharmacy directors, nurses, case managers, formulary directors, consultant pharmacists, and other managed markets decision makers from managed care organizations, pharmacy benefit managers, Medicare, hospitals, large employers, VA/DOD, and other managed markets segments.

Learning Objectives

After completing this activity, participants should be able to:

Define the prevalence and clinical and economic burden of chronic obstructive pulmonary disease (COPD) among the US adult population
Compare and contrast characteristics of COPD and asthma and the potential impact on disease management decisions
Summarize the GOLD and ATS/ERS guidelines for the prevention, diagnosis, and management of COPD
Outline the current HEDIS^® measure for COPD diagnosis and the 2008 measure on COPD management
Incorporate the latest evidence and guidelines to overcome barriers to adherence to HEDIS^® measures and improve COPD outcomes

The Healthcare Effectiveness Data and Information Set (HEDIS^®) is a tool used by more than 90 percent of America's health plans to measure performance on important dimensions of care and service.

HEDIS^® is a registered trademark of the National Committee for Quality Assurance (NCQA)

Credit Eligibility

To be eligible for documentation of credit, participants must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the online evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release date: February 7, 2008; Expiration date: February 11, 2009

Estimated time to complete: 1 hour

There is no fee associated with this activity.

Lecture Components

The presentation slides, post-test, and evaluation form are available as a click through via the menu at the top of each page of this educational activity.

This activity is made available on-line and in print.

CME Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the National Committee for Quality Assurance (NCQA) and Princeton CME. NCQA is accredited by the ACCME to provide continuing medical education for physicians.

NCQA designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This CME activity is recognized by the American Osteopathic Association for a maximum of 1 Category 2 credit.

CNE Accreditation

NCQA is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity is approved for 1.0 nursing education contact hour.

CPE Accreditation

Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UPN 452-999-08-001-H01-P).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity sponsored or cosponsored by Princeton CME may contact the Assistant Director of Continuing Education in writing. The Assistant Director of Continuing Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Director of Continuing Education may be made for a second level of review.

Grant Support

This activity is supported by and educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc.

Participating Faculty

Fernando J. Martinez, MD, MS
Professor of Internal Medicine
Medical Director, Pulmonary Diagnostic Services
Co-Medical Director, Lung Transplantation
Division of Pulmonary and Critical Care Medicine
University of Michigan Health System
Ann Arbor, Michigan

William F. Tulloch, MA
Director, Customer Resources
National Committee for Quality Assurance
Washington, DC

William J. Cardarelli, PharmD
Director of Pharmacy
Atrius Health
Harvard Vanguard Medical Associates
Watertown, Massachusetts

Independent Clinical Reviewer

Imre Noth, MD
Associate Professor of Medicine
University of Chicago
Section of Pulmonary and Critical Care Medicine
Chicago, Illinois

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NCQA and Princeton CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NCQA and Princeton CME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:
Dr. Martinez: Consultant—Altana Pharma, Genzyme; Speakers bureau—Astra Zeneca, Boehringer Ingelheim Pharmaceuticals, GlaxoSmithKline, Pfizer, Schering-Plough Corporation
Mr. Tulloch: Speakers bureau—Boehringer Ingelheim Pharmaceuticals, Pfizer
Drs. Cardarelli and Noth disclosed no relevant financial relationships with any commercial interests.

Planning Committee Jennifer D’Alessandro, MPA and Kathleen C. Mudd, RN, MBA, NCQA; Randy Robbin and John Savage, Princeton CME; and Mary Johnson and Stacey Ohana, Princeton Media Communications have disclosed that they have no significant financial relationships.

NCQA and Princeton CME require faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentations.

The faculty has disclosed that off-label/unapproved uses of fluticasone 500/salmeterol 50 will be discussed.